InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (11 ops.)
Explore the complete record of transactions filed by Seeto Reginald, President and Chief Executive Officer. Officer active across 1 companies, notably CareDx, Inc.. Aggregated, 32 filings have been published. Total volume traded: €1m. The latest transaction was filed on 21 March 2022 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations32 total
€105,7442,888 shares@ €36.61490.010% mcap2.9% of flow
Common Stock
SEC:0001217234-22-000068:0·
06,100 shares0
Common Stock
SEC:0001217234-22-000060:0·
€100,4782,550 shares@ €39.40330.0097% mcap5.7% of flow
Common Stock
SEC:0001217234-22-000046·
€100,4782,550 shares@ €39.40330.0097% mcap2.8% of flow
Common Stock
SEC:0001217234-22-000046:0·
€116,4253,182 shares@ €36.58880.011% mcap6.6% of flow
Common Stock
SEC:0001217234-22-000038·
€116,4253,182 shares@ €36.58880.011% mcap3.2% of flow
Common Stock
SEC:0001217234-22-000038:0·
€62,8071,818 shares@ €34.54730.0061% mcap3.6% of flow
Common Stock
SEC:0001217234-22-000030·
€62,8071,818 shares@ €34.54730.0061% mcap1.7% of flow
Common Stock
SEC:0001217234-22-000030:0·
€60,3661,719 shares@ €35.11680.0059% mcap3.4% of flow
Common Stock
SEC:0001217234-22-000022·
€60,3661,719 shares@ €35.11680.0059% mcap1.7% of flow
Common Stock
SEC:0001217234-22-000022:0·
€174,7774,624 shares@ €37.79790.017% mcap10.0% of flow
Common Stock
SEC:0001688485-21-000007·
€174,7774,624 shares@ €37.79790.017% mcap4.8% of flow
Common Stock
SEC:0001688485-21-000007:0·
€20,974494 shares@ €42.45840.0020% mcap1.2% of flow
Common Stock
SEC:0001217234-21-000237·
€20,974494 shares@ €42.45840.0020% mcap0.6% of flow
Common Stock
SEC:0001217234-21-000237:0·
€44,777658 shares@ €68.05060.0043% mcap2.6% of flow
Common Stock
SEC:0001217234-21-000208·
€44,777658 shares@ €68.05060.0043% mcap1.2% of flow
Common Stock
SEC:0001217234-21-000208:0·
€66,2723,247 shares@ €20.41020.0064% mcap3.8% of flow
Common Stock
SEC:0001217234-21-000206·
€66,2723,247 shares@ €20.41020.0064% mcap1.8% of flow
Common Stock
SEC:0001217234-21-000206:0·
€40,785592 shares@ €68.89310.0040% mcap2.3% of flow
Common Stock
SEC:0001217234-21-000198·
€40,785592 shares@ €68.89310.0040% mcap1.1% of flow
Common Stock
SEC:0001217234-21-000198:0·
€134,6761,880 shares@ €71.63620.013% mcap7.7% of flow
Common Stock
SEC:0001217234-21-000174·
€134,6761,880 shares@ €71.63620.013% mcap3.7% of flow
Common Stock
SEC:0001217234-21-000174:0·
€307,0434,006 shares@ €76.64580.030% mcap17.5% of flow
Common Stock
SEC:0001217234-21-000172·
€307,0434,006 shares@ €76.64580.030% mcap8.5% of flow
Common Stock
SEC:0001217234-21-000172:0·
€246,33610,602 shares@ €23.23490.024% mcap14.1% of flow
Common Stock
SEC:0001217234-21-000154·
25 of 32 declarations
About Seeto Reginald
Reginald Seeto is a life sciences executive best known for serving as President and Chief Executive Officer of CareDx, Inc., a U.S.-listed company focused on transplant diagnostics and precision medicine solutions. He joined CareDx in November 2018 as President and Chief Business Officer and was promoted to President and CEO in November 2020. He led the company through an important leadership transition and strategic growth phase, and later stepped down as CEO and from the board in November 2023, moving into the role of Senior Advisor to the Chairperson. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1217234/000119312520281060/d28203dex992.htm?utm_source=openai)) Before CareDx, Seeto served as Chief Operating Officer at Ardelyx, where he oversaw pre-commercialization efforts and corporate development, including strategic partnerships. Prior to that, he spent eight years at AstraZeneca and MedImmune in roles of increasing responsibility across strategy, global strategic marketing, portfolio management, and partnering; he also held a country leadership role in Thailand. Earlier in his career, he held senior marketing positions at Organon Biosciences and Boehringer Ingelheim, and he began his professional journey as a practicing physician and researcher in Australia. He earned both a B.S. and an MBBS in medical studies from the University of Sydney. ([ir.ardelyx.com](https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-strengthens-executive-leadership-appointment-reginald?utm_source=openai)) His background combines clinical training with deep operational and commercial leadership experience, giving him a broad perspective on biopharmaceutical and diagnostics strategy. Across his career, he has worked on corporate development, portfolio strategy, commercialization, and cross-functional execution in highly regulated healthcare environments. At CareDx, he helped strengthen the company’s business operations and strategic positioning within transplant care, supporting a patient-centric mission and the scaling of precision diagnostics for a specialized market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1217234/000119312520281060/d28203dex992.htm?utm_source=openai))
